New treatment for rare forms of leukaemia available across Scotland

ARIAD today welcomed the Scottish Medicine Consortium’s (SMC) acceptance to use Iclusig® (ponatinib) as a clinical and cost effective treatment for all phases of chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), in accordance with Iclusig’s licenced indication.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Haematology Oncology Patient care chronic myeloid leukaemia Latest News philadelphia chromosome positive ponatinib Source Type: news